BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 17, 2024
app pub date -
Mar 14, 2024
filing date -
Mar 14, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The disclosed invention relates to compositions and methods of administration to a subject, with bisbenzylisoquinolines such as 6,6′,7,12-tetramethoxy-2,2′-dimethyl-berbaman (tetrandrine, TET and ES-3000), and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents which modulate β-catenin and/or CaMKIIγ levels to either improve therapeutic outcome by enhancing expression of targets and/or decrease side effects of therapeutic regimens involving immunotherapies, such as checkpoint inhibitors and Chimeric antigen receptor T-cells (CAR-T).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully